Fox Chase Cancer Center Researcher Presents Study on Optimizing Phase 1 Clinical Trial Workload Management

Shannon Fabrie
Shannon Fabrie, BS, project lead and Disease Site Research Manager for phase 1 trials at Fox Chase Cancer Center

PHILADELPHIA (July 8, 2025) — A new method of assessing workloads for clinical researchers at Fox Chase Cancer Center has proven effective in mitigating workload imbalances and improving phase 1 clinical programs. The findings of this project were presented at the Association of American Cancer Institutes’ (AACI) Clinical Research Innovation (CRI) Annual Meeting.

A phase 1 clinical trial is the first step in testing a potential new drug in humans. The phase 1 program at Fox Chase, which is part of its Office of Clinical Research, plays an essential role in the early development of clinical trials. During this phase, researchers test new treatments to evaluate them for safety and appropriate dosage. 

“This study came about because there didn’t seem to be a very robust system on how we were assigning studies and how we were assessing workload per study,” said Shannon Fabrie, BS, project lead and Disease Site Research Manager for phase 1 trials at Fox Chase. “Other systems just don’t work very well for phase 1 studies because they rank all phase 1 studies in one singular category.”

To improve on this, Fabrie designed the Oncology - Phase 1 Acuity Scoring System (O-PASS), a method aimed at improving workload distribution and ultimately expanding patient access to clinical trials.

O-PASS features a rubric that allows managers to evaluate each phase 1 clinical trial using 20 study-specific criteria on a standardized scoresheet. The scoresheet gives each clinical trial a weighted score that can then be used to assign studies to research coordinators according to the estimated workload outlined by the rubric.

“Using O-PASS allows me as a manager to clearly compare the workloads of my clinical research coordinators and clinical research nurses so that I may assess how best to balance the portfolio. I can also better assign high acuity studies to those with more experience that may be at a higher position level than others on the team,” said Fabrie.

In addition to using the rubric, Fabrie has also given her team assessment questionnaires to see whether this method has improved their work-life balance and whether the workload was fair and thoughtful. 
“The feedback has been really positive so far,” said Fabrie. “The plan is to continue to assess the quality of work-life balance with similar questionnaires every six months and then hopefully expand the use of O-PASS to data specialists.” 

The 17th Annual AACI CRI meeting was held June 23-25, in Chicago.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427